Robert Schwartz

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

InterValve, Inc. operates as a medical device company which develops aortic valvuloplasty balloons for treatment of calcific aortic stenosis. Its V8 product is enhanced with leaflet hyperextension without increasing the risk of annulus over-distension. The firm also develops tools for the percutaneous and trans-apical aortic valve replacement procedure. The company was founded by Wes Pedersen, Mark Ungs, Robert S. Schwartz and Robert A. Van Tassel in 2008 and is headquartered in Plymouth, MN.

Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota.

Mayo Foundation for Medical Education & Research operates as a medical care research and education organization. Its services include patient care, corporate services, research, and education. The company was founded in 1984 and is headquartered in Rochester, MN.

Tricardia Ventures LLC provides investment services. It seeks to acquire in the development of promising technology in the field of cardiovascular medicine. The company is headquartered in Eden Prairie, MN.